vlx1570

VLX1570 is a small molecule inhibitor of the 19S proteasome deubiquitinases (DUBs), specifically targeting ubiquitin-specific protease 14 (USP14) and ubiquitin carboxyl-terminal hydrolase isozyme L5 (UCHL5). It acts as a competitive and reversible inhibitor, leading to accumulation of polyubiquitinated proteins and ultimately inducing apoptosis in cancer cells. VLX1570 was developed for its potential to overcome resistance to conventional proteasome inhibitors in multiple myeloma. Preclinical studies demonstrated anti-tumor activity in models resistant to standard therapies. Clinical development was halted due to severe pulmonary toxicity observed at higher doses[2][8][9].

Other names

(3E,5E)-3,5-Bis[(4-Fluoro-3-Nitrophenyl)Methylidene]-1-(Prop-2-Enoyl)Azepan-4-One